Antibody protection: passive immunization of neonates against oral AIDS virus challenge.
about
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesStructure-Based Design of a Protein Immunogen that Displays an HIV-1 gp41 Neutralizing EpitopeThe rhesus macaque pediatric SIV infection model - a valuable tool in understanding infant HIV-1 pathogenesis and for designing pediatric HIV-1 prevention strategiesHIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies.Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1.Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.Limited contribution of mucosal IgA to Simian immunodeficiency virus (SIV)-specific neutralizing antibody response and virus envelope evolution in breast milk of SIV-infected, lactating rhesus monkeysRobust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeysEvidence for persistent, occult infection in neonatal macaques following perinatal transmission of simian-human immunodeficiency virus SF162P3Novel peptide-based HIV-1 immunotherapy.Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.Monoclonal antibody-based candidate therapeutics against HIV type 1.Antibody-mediated immunomodulation: a strategy to improve host responses against microbial antigensRefined identification of neutralization-resistant HIV-1 CRF02_AG viruses.Accelerated heterologous adenovirus prime-boost SIV vaccine in neonatal rhesus monkeys.Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding SitesGB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolatesIdentification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes.Prevention of the sexual transmission of HIV-1: preparing for success.A simple one-step method for the preparation of HIV-1 envelope glycoprotein immunogens based on a CD4 mimic peptide.Lack of B cell dysfunction is associated with functional, gp120-dominant antibody responses in breast milk of simian immunodeficiency virus-infected African green monkeys.A neonatal oral Mycobacterium tuberculosis-SIV prime / intramuscular MVA-SIV boost combination vaccine induces both SIV and Mtb-specific immune responses in infant macaques.Humoral Antibody Responses to HIV Viral Proteins and to CD4 Among HIV Controllers, Rapid and Typical Progressors in an HIV-Positive Patient Cohort.Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro.
P2860
Q24561905-421280F2-96AB-4495-989B-2543D7FCCD58Q27675260-2D60969D-7A40-4AF0-9D7A-A456E729D0CEQ30374404-DA648CBB-37F3-4A0A-A72F-CE24A780B787Q30381447-CC06D761-E8BD-4C37-99F0-9EDFFD5545EFQ33205911-C8241D0C-96EB-4409-BCAA-7459E7A4A63CQ33518005-FE32C508-396F-4B41-92E3-29BE4DCFB600Q33895810-BB33936E-6299-428C-AFD4-39BF22275D32Q33984182-4574E789-783F-4792-90E1-97B97A0010B5Q34046182-3920F989-6AB8-4F8D-A6BA-DD52498B31F0Q34474475-AE61B5D4-DF7F-441C-B5BB-AB3E5B85F528Q35635083-B13EB7E6-7320-4613-B344-46D199158357Q35684864-66A6EF00-A37E-42BA-8450-16FA830BBB60Q35867981-85875A82-604D-4BDF-8817-448AEC45CD61Q35904501-3A1F7C45-A6CC-43A4-8F6E-890603E6686AQ36017488-090705C5-FB5B-4120-B25E-B709B7E56CF6Q36155365-BC0D1C7C-8686-4D31-9F71-B42758032F5FQ36171869-9567FEF7-F193-477F-8488-C6333DC2103BQ36434294-FF0D1D74-3882-4B42-AE9F-7D058DE696CDQ36530370-96C4569E-180C-4E74-8692-57B5F96D83C7Q36827300-45C10B84-9C79-4985-9A89-0B51E2F84D2AQ36975282-8C5C0AB8-3065-47A5-B107-58609FFD1FF9Q37102810-9FDC7E6B-48A8-4B13-994B-434283FA7CBDQ37252604-E0050197-0A2A-4F74-8842-1BB9356870FFQ37490057-5A40CD87-8CA7-4527-BCD5-1E514E95996AQ37523341-80435DD4-CCFB-4F16-9FD9-F4732BBF92B3Q40370913-AFC1037D-FB28-4CED-AB12-191805CFE8BE
P2860
Antibody protection: passive immunization of neonates against oral AIDS virus challenge.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Antibody protection: passive immunization of neonates against oral AIDS virus challenge.
@ast
Antibody protection: passive immunization of neonates against oral AIDS virus challenge.
@en
type
label
Antibody protection: passive immunization of neonates against oral AIDS virus challenge.
@ast
Antibody protection: passive immunization of neonates against oral AIDS virus challenge.
@en
prefLabel
Antibody protection: passive immunization of neonates against oral AIDS virus challenge.
@ast
Antibody protection: passive immunization of neonates against oral AIDS virus challenge.
@en
P2093
P1433
P1476
Antibody protection: passive immunization of neonates against oral AIDS virus challenge
@en
P2093
Harold M McClure
Moiz Kitabwalla
Ruth M Ruprecht
Weidong Xu
P304
P356
10.1016/S0264-410X(03)00335-9
P407
P577
2003-07-01T00:00:00Z